Sen. Markwayne Mullin Sells Off Shares of Danaher Co. (NYSE:DHR)

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on February 27th, the Senator disclosed that they had sold between $15,001 and $50,000 in Danaher stock on February 13th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 2/13/2025.
• Purchased $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Brick (TSE:BRK) on 2/13/2025.
• Sold $100,001 – $250,000 in shares of Vanguard Materials ETF (NYSEARCA:VAW) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of Microsoft (NASDAQ:MSFT) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of LPL Financial (NASDAQ:LPLA) on 2/13/2025.
• Purchased $15,001 – $50,000 in shares of TJX Companies (NYSE:TJX) on 2/13/2025.
• Sold $50,001 – $100,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 2/13/2025.

Danaher Stock Performance

DHR stock opened at $207.73 on Friday. The company has a market cap of $148.47 billion, a P/E ratio of 39.34, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock’s fifty day moving average price is $224.58 and its 200-day moving average price is $244.92.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company posted $2.09 EPS. On average, equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is 24.24%.

Institutional Investors Weigh In On Danaher

Large investors have recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new stake in Danaher during the fourth quarter worth approximately $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher during the fourth quarter worth approximately $31,000. Golden State Wealth Management LLC bought a new stake in Danaher during the fourth quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the third quarter worth approximately $39,000. Finally, Hurley Capital LLC bought a new stake in Danaher during the fourth quarter worth approximately $34,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on DHR shares. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Jefferies Financial Group lowered their target price on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Royal Bank of Canada reiterated an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. JPMorgan Chase & Co. lowered their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Guggenheim assumed coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $278.00.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is currently owned by insiders.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.